Millennium Management LLC Has $1.37 Million Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Millennium Management LLC raised its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 52.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 859,825 shares of the company’s stock after purchasing an additional 297,351 shares during the quarter. Millennium Management LLC owned approximately 0.95% of Caribou Biosciences worth $1,367,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CRBU. Centric Wealth Management acquired a new stake in Caribou Biosciences during the 4th quarter valued at approximately $27,000. Russell Investments Group Ltd. grew its position in shares of Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after buying an additional 21,416 shares during the period. MetLife Investment Management LLC grew its position in shares of Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after buying an additional 9,148 shares during the period. Diametric Capital LP acquired a new stake in shares of Caribou Biosciences during the 4th quarter worth approximately $42,000. Finally, US Bancorp DE grew its position in shares of Caribou Biosciences by 3,524.2% during the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after buying an additional 26,467 shares during the period. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Stock Up 7.7%

Shares of CRBU stock opened at $1.05 on Wednesday. The company has a market cap of $97.66 million, a price-to-earnings ratio of -0.64 and a beta of 2.36. Caribou Biosciences, Inc. has a 52 week low of $0.66 and a 52 week high of $3.00. The firm has a 50 day moving average of $0.88 and a 200-day moving average of $1.31.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.